Table 3.
Incremental cost-effectiveness of monotherapy vs. combination therapy over 20 years, by presenting visual acuity.
| Total Cost (SGD) | Incremental Cost (SGD) | QALYs | Incremental QALYs | ICER (SGD/QALY) | |
|---|---|---|---|---|---|
| All eyes | |||||
| Monotherapy | 48,792 | NA | 7.41 | NA | NA |
| Combination therapy | 61,017 | 12,225 | 7.80 | 0.39 | 31,459 |
| 20/20 to 20/40 | |||||
| Monotherapy | 86,593 | NA | 8.46 | NA | Dominated |
| Combination therapy | 66,325 | −20,268 | 8.51 | 0.06 | NA |
| 20/50 to 20/80 | |||||
| Monotherapy | 57,811 | NA | 7.62 | NA | NA |
| Combination therapy | 67,200 | 9389 | 7.96 | 0.34 | 27,953 |
| 20/100 to 20/160 | |||||
| Monotherapy | 46,844 | NA | 7.21 | NA | NA |
| Combination therapy | 62,411 | 15,567 | 7.58 | 0.36 | 42,696 |
| Worse than 20/160 | |||||
| Monotherapy | 17,195 | NA | 6.63 | NA | NA |
| Combination therapy | 52,494 | 35,299 | 7.30 | 0.67 | 52,782 |
QALY Quality-adjusted life-year, ICER Incremental cost-effectiveness ratio.